

# We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

4,800

Open access books available

122,000

International authors and editors

135M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index  
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?  
Contact [book.department@intechopen.com](mailto:book.department@intechopen.com)

Numbers displayed above are based on latest data collected.

For more information visit [www.intechopen.com](http://www.intechopen.com)



# Role of Ceramide 1-Phosphate in the Regulation of Cell Survival and Inflammation

Alberto Ouro, Lide Arana, Patricia Gangoiti and Antonio Gomez-Muñoz  
*Department of Biochemistry and Molecular Biology  
Faculty of Science and Technology, University of the Basque Country, Bilbao  
Spain*

## 1. Introduction

Cell and tissue homeostasis is essential for normal development of an organism. When this is altered, metabolic dysfunctions and disease are prone to occur. Therefore, the maintenance of an appropriate balance in the activation / inhibition of the different metabolic pathways and cell signaling systems is simply vital.

Many lipids, including simple sphingolipids, are known to regulate cell activation and metabolism (Gomez-Munoz et al., 1992; Gomez-Munoz, 1998; Gomez-Munoz, 2004; Gomez-Munoz, 2006; Hannun & Obeid, 2008; Chen et al., 2011; Hannun & Obeid, 2011). Some of them, including sphingosine, ceramides and their phosphorylated forms, sphingosine 1-phosphate (S1P) and ceramide 1-phosphate (C1P) have been described as crucial regulators of key processes that are essential for normal development, and have also been involved in the establishment and progression of different diseases (Gangoiti et al., 2008a; Arana et al., 2010). In particular, ceramides can induce cell growth arrest and cause apoptosis, when they are generated (Hannun et al., 1986; Kolesnick, 1987; Kolesnick & Hemer, 1990; Merrill & Jones, 1990; Merrill, 1991; Hannun, 1994; Kolesnick & Golde, 1994; Hannun & Obeid, 1995; Hannun, 1996; Spiegel & Merrill, 1996; Merrill et al., 1997; Kolesnick et al., 2000; Hannun & Obeid, 2002; Merrill, 2002). Nonetheless, although in general, ceramides are negative signals for cell survival, in neurons they can induce cell growth (Goodman & Mattson, 1996; Ping & Barrett, 1998; Brann et al., 1999; Song & Posse de Chaves, 2003; Plummer et al., 2005). Also, ceramides play important roles in the regulation of cell differentiation, inflammation, tumor development (Okazaki et al., 1990; Mathias et al., 1991; Dressler et al., 1992; Hannun, 1994; Kolesnick & Golde, 1994; Hannun & Obeid, 1995; Gomez-Munoz, 1998; Menaldino et al., 2003), bacterial and viral infections, and ischemia-reperfusion injury (Gulbins & Kolesnick, 2003). More recently, ceramides have been associated with insulin resistance through activation of protein phosphatase 2A and the subsequent dephosphorylation and inactivation of protein kinase B (PKB) (Schmitz-Peiffer, 2002; Adams et al., 2004; Stratford et al., 2004), and toll-like receptor 4 (TLR4)-dependent induction of inflammatory cytokines, a fact essential for TLR4-dependent insulin resistance (Holland et al., 2011).

Concerning ceramide generation, there are three different mechanisms by which these molecules can be synthesized in cells. Ceramides can be generated by i) *de novo* synthesis,

which takes place in the endoplasmic reticulum (ER), ii) by the action of different sphingomyelinases (SMases) in the plasma membrane, lysosomes, or mitochondria, and iii) by reacylation of sphingosine, a pathway known as the salvage or recycled pathway (Hannun & Obeid, 2011). The biosynthetic and degradative pathways of ceramide are shown in figure 1, where further products of ceramide metabolism are also indicated.

Natural ceramides typically have long *N*-acyl chains ranging from 16 to 26 carbons in length (Merrill, 2002; Pettus et al., 2003a; Merrill et al., 2005), and some times longer in tissues such as skin. Many studies have used a short-chain analog (N-acetylsphingosine, or C<sub>2</sub>-ceramide) in experiments with cells in culture because it can be incorporated into cells more easily and rapidly than long-chain ceramides. Of note, although C<sub>2</sub>-ceramide was suggested not to occur *in vivo*, recent studies demonstrated that C<sub>2</sub>-ceramide does exist in mammalian tissues. In particular, C<sub>2</sub>-ceramide was found in rat liver cells (Merrill et al., 2001; Van Overloop et al., 2007), and brain tissue (Van Overloop et al., 2007). Ceramide generation is also relevant because this sphingolipid is the precursor of important bioactive molecules that can also regulate cellular functions. For instance, stimulation of ceramidases results in generation of sphingosine (Fig. 1), which was first described as a physiological inhibitor of protein kinase C (PKC) (Hannun et al., 1986). There are numerous reports in the scientific literature showing that PKC is inhibited by exogenous addition of sphingosine to cells in culture. Moreover, Merrill and co-workers demonstrated that addition of the ceramide synthase inhibitor fumonisin B1 to J774.A1 macrophages to increase the levels of endogenous sphingoid bases, also inhibited protein kinase C (Smith et al., 1997). Further work showed that sphingosine can affect the activity of other important enzymes that are involved in the regulation of metabolic or cell signaling pathways such as the Mg<sup>2+</sup> dependent form of phosphatidate phosphohydrolase (Jamal et al., 1991; Gomez-Munoz et al., 1992), phospholipase D (PLD) (Natarajan et al., 1994), or diacylglycerol kinase (DAGK) (Sakane et al., 1989; Yamada et al., 1993). Sphingosine, in turn, can be phosphorylated by the action of sphingosine kinases to generate S1P, which is a potent mitogenic agent and can also inhibit apoptosis in many cell types (Olivera & Spiegel, 1993; Wu et al., 1995; Spiegel et al., 1996; Spiegel & Merrill, 1996; Spiegel & Milstien, 2002; Spiegel & Milstien, 2003). More recently, we demonstrated that S1P stimulates cortisol (Rabano et al., 2003) and aldosterone secretion (Brizuela et al., 2006) in cells of the zona fasciculata or zona glomerulosa, respectively, of bovine adrenal glands, suggesting that S1P plays an important role in the regulation of steroidogenesis.

A major metabolite of ceramide in cells is ceramide-1-phosphate (C1P), which is formed directly through phosphorylation of ceramide by the action of ceramide kinase (CerK) (Fig. 1). There is increasing evidence suggesting that C1P can regulate cell proliferation and apoptosis (Reviewed in (Gomez-Munoz, 1998; Gomez-Munoz, 2004)), and Chalfant and co-workers have implicated C1P in inflammatory responses (Reviewed in (Chalfant & Spiegel, 2005; Lamour & Chalfant, 2005)). In addition, Shayman's group demonstrated that C1P plays a key role in phagocytosis (Hinkovska-Galcheva & Shayman; Hinkovska-Galcheva et al., 1998; Hinkovska-Galcheva et al., 2005).

The aim of the present chapter is to review and update recent progress on the regulation of cell survival and inflammation by C1P.




Fig. 1. Biosynthesis of simple sphingolipids in mammalian cells. Ceramide is the central core of sphingolipid metabolism. It can be produced by *de novo* synthesis through the concerted action of serine palmitoyltransferase and dihydroceramide synthase or by degradation of sphingomyelin (SM) through sphingomyelinase (SMase) activation. Ceramides can also be generated through metabolism of more complex sphingolipids. Phosphorylation of ceramide by ceramide kinase gives rise to ceramide-1-phosphate. The reverse reaction is catalyzed by ceramide-1-phosphate phosphatase, or by lipid phosphate phosphatases. Alternatively, ceramide can be degraded by ceramidases to form sphingosine, which can, in turn, be phosphorylated to sphingosine-1-phosphate by sphingosine kinases. The reverse reaction is catalyzed by sphingosine-1-phosphate phosphatases, or by lipid phosphate phosphatases. Sphingosine-1-phosphate lyase breaks down Sphingosine-1-phosphate to hexadecenal and ethanolamine phosphate, both of which can be recycled back to generate phosphatidylethanolamine. Sphingomyelin *N*-deacylase generates sphingosylphosphorylcholine, also known as lysosphingomyelin.

## 2. Biosynthesis of ceramide 1-phosphate. The essential role of ceramide kinase

At present, the only enzyme known to produce C1P in mammalian cells is ceramide kinase (CerK). This enzyme was first observed in brain synaptic vesicles (Bajjalieh et al., 1989), and was later found in human leukemia HL-60 cells (Kolesnick & Hemer, 1990). CerK was first reported to be confined to the microsomal membrane fraction, but more recent studies indicate that it is mainly located in the cytosol (Mitsutake et al., 2004). These contradictory observations may arise from the different degrees of enzyme expression in different cell types, and it may also be possible that subcellular localization of this enzyme varies depending on cell metabolism. In this connection, Van Veldhoven and co-workers found that tagged forms of human CerK (FLAG-HsCerK and EGFP-HsCerK fusions), upon expression in Chinese Hamster Ovary (CHO) cells, were mainly localized to the plasma membrane, whereas no evidence for association with the ER was observed (Van Overloop et al., 2006). These findings are in agreement with those of Boath et al. (Boath et al., 2008) who showed that ceramides are not phosphorylated at the ER but must be transported to the Golgi apparatus for phosphorylation by CerK. When C1P is synthesized, it traffics from the Golgi network along the secretory pathway to the plasma membrane, where it can be back-exchanged into the extracellular environment and then bind to acceptor proteins such as albumin or lipoproteins (Boath et al., 2008). These observations are consistent with published work by Chalfant's group (Lamour et al., 2007), and it was demonstrated that CerK utilizes ceramide transported to the trans-Golgi apparatus by ceramide transport protein (CERT). In fact, downregulation of CERT by RNA interference resulted in strong inhibition of newly synthesized C1P, suggesting that CERT plays a critical role in C1P formation. However, Boath et al (Boath et al., 2008) reported that the transport of ceramides to the vicinity of CerK is not dependent upon CERT intervention. The reason for such discrepancy is unknown at the present time, but it is possible that the different experimental approaches used in those studies rendered different results. Specifically, whilst Lamour and co-workers used siRNA technology to inhibit CERT (Lamour et al., 2007), Boath and co-workers utilized pharmacological inhibitors (Boath et al., 2008). Also, it might be possible that different cell types may have different subcellular distribution of CerK, and / or that expression of this enzyme activity is not the same in all cell types.

With regards to the regulation of CerK, its ability to move intracellularly from one compartment to another and the dependency on cations (mainly  $\text{Ca}^{2+}$  ions) for activity seem to be well established. More recently, CerK has been proposed to be regulated by phosphorylation/dephosphorylation processes (Baumruker et al., 2005), and that it can be myristoylated at its N-terminus, a feature that is related to targeting proteins to membranes. Nonetheless, cleavage of the myristoylated moiety did not affect the intracellular localization of the enzyme. In addition, both CerK location and activity seem to require the integrity of its PH domain, which actually includes the myristoylation site, as deletion of this domain abolishes both the specific subcellular localization of the enzyme, as well as its activity (Baumruker et al., 2005).

Although CerK is thought to be the only enzyme for production of C1P, it was reported that bone marrow-derived macrophages (BMDM) from CerK-null mice (CerK<sup>-/-</sup>) still had significant levels of C1P (Boath et al., 2008). This observation suggests that there are other metabolic pathways, at least in mammals, capable of generating C1P independently of CerK.



Specifically, formation of C<sub>16</sub>-C1P, which is a major species of C1P in cells, was not abolished in CerK<sup>-/-</sup> BMDM. Two alternative pathways for generation of C1P in cells might be: i) acylation of S1P by a putative acyl transferase that would catalyze the formation of a N-linked fatty acid in the S1P moiety to form C1P, and ii) cleavage of sphingomyelin (SM) by the action of a D-type SMase (SMase D), which would generate choline and C1P in an analogous manner to that of phospholipase D acting on phosphatidylcholine to produce choline and phosphatidic acid (PA). However, work from our own lab (Gomez-Munoz et al., 1995a) and that of others (Boath et al., 2008) demonstrated that acylation of S1P to form C1P does not occur in mammalian cells. Also, formation of C1P by the action of a putative SMase D has not yet been reported for mammalian cells. SMase D is a major component of the venom of a variety of arthropods including spiders of the genus *Loxosceles* (the brown recluse spider), such as *L. reclusa*. SMase D is also present in the toxins of some bacteria including *Corynebacterium pseudotuberculosis*, or *Vibrio damsela* (Truett & King, 1993). The bites of this spider result in strong inflammatory responses and may lead to renal failure, and occasionally lead to death (Lee & Lynch, 2005). Although we found no evidence for an analogous activity of SMase D in rat fibroblasts (Gomez-Munoz et al., 1995a), this possibility should be explored in more detail using different types of cells; so it is possible that SMase D may still be the cause for C1P generation in selective tissues.

Concerning regulation, mammalian CerK was demonstrated to be highly dependent on Ca<sup>2+</sup> ions for activity (Van Overloop et al., 2006). More recently, it has been shown that treatment of human lung adenocarcinoma A549 cells and Chinese hamster ovary cells (CHO) with orthovanadate, a potent inhibitor of tyrosine phosphatases, increased CerK expression potently (Tada et al., 2010), suggesting a possible regulation of CerK by phosphorylation/dephosphorylation processes on tyrosine residues. Also, it has been suggested that CerK expression can be regulated through activation of Toll-like receptor 4 (TLR-4) by agonists such as the bacterial toxin lipopolysaccharide (Rovina et al., 2010).

The cloning of CerK (Sugiura et al., 2002) opened a new avenue of research that led to determination of important structural properties of this enzyme. The protein sequence has 537 amino acids with two protein sequence motifs, an N-terminus pleckstrin homology (PH) domain, and a C-terminal region containing a Ca<sup>2+</sup>/calmodulin binding domain. Using site-directed mutagenesis, it was found that leucine 10 in the PH domain is essential for the catalytic activity of CerK (Kim et al., 2005). In addition, it was reported that the interaction between the PH domain of CERK and phosphatidylinositol 4,5-bisphosphate regulates the plasma membrane targeting and the levels of C1P (Kim et al., 2006). CERK also contains the five conserved sequence stretches (C1-C5) that are specific for lipid kinases (Reviewed in (Baumruker et al., 2005)).

With regards to substrate specificity, it was reported that phosphorylation of ceramide by CERK is stereospecific (Wijesinghe et al., 2005). The latter report also showed that a minimum of a 12-carbon acyl chain was required for normal CERK activity, whereas the short-chain ceramide analogues C<sub>8</sub>-ceramide, C<sub>4</sub>-ceramide, or C<sub>2</sub>-ceramide were poor substrates for CERK. It was concluded that CERK phosphorylates only the naturally occurring D-erythro-ceramides (Wijesinghe et al., 2005). However, C<sub>2</sub>-ceramide has been shown to also be a good substrate for CerK, especially when albumin is used as a carrier, and that C<sub>2</sub>-ceramide can be converted to C<sub>2</sub>-C1P within cells (Van Overloop et al., 2007). This raises the possibility that C<sub>2</sub>-C1P is also a natural sphingolipid, capable of eliciting

important biologic effects, as previously demonstrated (i.e. stimulation of cell proliferation (Gomez-Munoz et al., 1995a)). These observations suggested that substrate presentation is an important factor when testing CerK activity and that the use of different vehicles may result in different outcomes. Also, it should be borne in mind that CerK expression may not be the same in all cell types. The importance of CERK in cell signaling was emphasized in experiments using specific small interfering RNA (siRNA) to silence the gene encoding for CerK. Downregulation of CerK blocked the response of the enzyme to treatment with ATP, the calcium ionophore A23187, or interleukin 1-beta (Pettus et al., 2003b; Chalfant & Spiegel, 2005), and led to a potent inhibition of arachidonic acid release and PGE<sub>2</sub> formation in A549 lung adenocarcinoma cells. The relevance of CerK in cell biology was also highlighted in studies using CerK null mice; specifically, a potent reduction in the amount of neutrophils in the blood and spleen of these animals compared to their wild type counterparts was observed, whereas the amount of leukocytes, other than neutrophils, was increased in those mice. These observations suggested an important role of CerK in neutrophil biology (Graf et al., 2008). In addition to CerK, a ceramide kinase-like (CERKL) protein was identified in human retina (Tuson et al., 2004), and this was subsequently cloned (Bornancin et al., 2005). However, CERKL failed to phosphorylate ceramide or other related lipids, under conditions commonly used to measure CERK activity. Therefore, the role of this protein in cell biology is unclear at the present time.

CerK has also been reported to exist in dicotyledonous plants, where it was associated to the regulation of cell survival (Bi et al., 2011). Also, it has been recently found that a conserved cysteine motif is critical for rice CerK activity and function (Bi et al., 2011). However, no reports on the possible existence of CerK in monocot plants are available at the present time.

### 3. Catabolism of ceramide 1-phosphate

From the above discussion, it should be apparent that C1P is a bioactive metabolite, capable of altering cell metabolism rapidly and potently. So, the existence of enzymes capable of degrading C1P seemed to be feasible for regulation of C1P levels. The identification of a specific C1P phosphatase in rat brain (Shinghal et al., 1993), and hepatocytes (Boudker & Futerman, 1993), together with the existence of CerK suggested that ceramide and C1P are interconvertible in cells. C1P phosphatase is enriched in brain synaptosomes and liver plasma membrane fractions, and appeared to be distinct from PA phosphohydrolase, the phosphatase that hydrolyzes PA. Nonetheless, C1P can also be converted to ceramide by the action of a PA phosphohydrolase that is specifically located in the plasma membrane of cells (Waggoner et al., 1996). The latter enzyme belongs to a family of at least three mammalian lipid phosphate phosphatases (LPPs) (Brindley & Waggoner, 1998). LPPs have recently been shown to regulate cell survival by controlling the levels of intracellular PA and S1P pools (Long et al., 2005), and also to regulate leukocyte infiltration and airway inflammation (Zhao et al., 2005). Dephosphorylation of C1P might be a way of terminating its regulatory effects, although the resulting formation of ceramide could potentially be detrimental for cells. Controlling the levels of ceramide and C1P by the coordinated action of CERK and C1P phosphatases, may be of crucial importance for the metabolic or signaling pathways that are regulated by these two sphingolipids. It could be speculated that another possibility for degradation of C1P might be its deacylation to S1P, which could then be cleaved by lyase activity to render a fatty aldehyde and ethanolamine phosphate (Merrill & Jones, 1990), or to

sphingosine by the action of S1P phosphatases (Fig. 1). However, no C1P deacylases or lyases have so far been identified in mammalian tissues, suggesting that the only pathway for degradation of C1P in mammals is through phosphatase activity.

#### 4. Ceramide 1-phosphate and the control of cell growth and death

The first report showing that C1P was biologically active was published in 1995 (Gomez-Munoz et al., 1995a). C1P was found to have mitogenic properties as it stimulated DNA synthesis and cell division in rat or mouse fibroblasts (Gomez-Munoz et al., 1995a; Gomez-Munoz et al., 1997). Subsequent studies using primary macrophages, demonstrated that like for most growth factors, the mechanisms whereby C1P exerted its mitogenic effects implicated stimulation of the mitogen-activated protein kinase kinase (MEK)/Extracellularly regulated kinases 1-2 (ERK1-2), phosphatidylinositol 3-kinase (PI3-K)/protein kinase B (PKB, also known as Akt), and c-Jun terminal kinase (JNK) pathways (Gangoiti et al., 2008b). In addition, C1P caused stimulation of the DNA binding activity of the transcription factor NF- $\kappa$ B, and the selective inhibitors of MEK, PI3-K, and JNK (PD98059, LY290042, and SP600125), respectively) completely blocked NF- $\kappa$ B activation. Another major target of PKB is glycogen synthase kinase-3 $\beta$  (GSK-3 $\beta$ ), which expression was increased in the presence of C1P. This led to up-regulation of cyclin D1, and c-Myc, two important markers of cell proliferation that are targets of GSK-3 $\beta$ .

In addition, we found that C1P-stimulated macrophage proliferation, involved activation of sphingomyelin synthase (SMS), an enzyme that catalyzes the transfer of phosphocholine from phosphatidylcholine (PC) to ceramide to synthesize sphingomyelin (SM). The other by-product of this reaction is diacylglycerol (DAG), which is a well-established activator of protein kinase C (PKC). Conventional and novel PKC isoforms respond to DAG by translocating to the plasma membrane so that these enzymes can then express their activity and act on signaling events. In this connection, C1P stimulated the translocation and activation of the alpha isoform of PKC (PKC- $\alpha$ ) in macrophages, and this resulted to be essential for stimulation of cell growth by C1P (Gangoiti et al., 2010c).

In a more recent report, it has been demonstrated that another essential kinase involved in the regulation of cell proliferation by C1P is the mammalian target of rapamycin (mTOR) (Gangoiti et al., 2010a). Activation of this kinase was tested by measuring the phosphorylation state of its downstream target p70S6K after treatment with C1P. Activation of mTOR/ p70S6K was dependent upon prior activation of PI3-K, as selective inhibition of this kinase blocked mTOR phosphorylation and activation. In addition, C1P caused phosphorylation of PRAS40, a component of the mTOR complex 1 (mTORC1) that is absent in mTORC2, and inhibition of the small G protein Ras homolog enriched in brain (Rheb), which is also a specific component of mTORC1, completely blocked C1P-stimulated mTOR phosphorylation, DNA synthesis and macrophage growth. C1P also caused phosphorylation of another Ras homolog gene family member, RhoA, and inhibition of its downstream effector RhoA-associated kinase (ROCK) also blocked C1P-stimulated mTOR and cell proliferation. It was concluded that mTORC1, and RhoA/ROCK are essential components of the mechanism whereby C1P stimulates macrophage proliferation. However, phospholipase D (PLD), and cAMP are not involved in the mitogenic effect of C1P (Gomez-Munoz et al., 1995a; Gomez-Munoz et al., 1997). Concerning intracellular calcium levels, which have also been implicated in the regulation of cell proliferation, the situation is controversial.



Although short-chain C1Ps failed to induce  $\text{Ca}^{2+}$  mobilization in fibroblasts (Gomez-Munoz et al., 1995a; Gomez-Munoz et al., 1997) or neutrophils (Rile et al., 2003), and natural  $\text{C}_{16}$ -C1P did not alter intracellular  $\text{Ca}^{2+}$  concentrations in A549 cells (Pettus et al., 2004),  $\text{C}_2$ -C1P- or  $\text{C}_8$ -C1P, caused intracellular  $\text{Ca}^{2+}$  mobilization in calf pulmonary artery endothelial (CAPE) cells (Gijbsbers et al., 1999), thyroid FRTL-5 (Hogback et al., 2003), or Jurkat T-cells (Colina et al., 2005), suggesting that regulation of  $\text{Ca}^{2+}$  homeostasis may be cell type specific.

Finally, it should be pointed out that C1P has been recently shown to be a key mediator in the development and survival of retina photoreceptors, and to also play a critical role in photoreceptor differentiation (Miranda et al., 2011)

Apart from its mitogenic effect, another mechanism by which C1P controls cell homeostasis is by prevention of apoptosis (reviewed in (Gangoiti et al., 2010b)). We previously demonstrated that natural C1P blocked apoptosis in bone marrow-derived macrophages (Gomez-Munoz et al., 2004; Gomez-Munoz et al., 2005), and this was confirmed by Mitra and co-workers (Mitra et al., 2007) who found that down-regulation of CerK in mammalian cells reduced growth, and promoted apoptosis. Also, downregulation of CerK blocked epithelial growth factor-induced cell proliferation. However, in contrast to these observations, it was reported that addition of the cell-permeable  $\text{C}_2$ -ceramide to cells overexpressing CerK led to  $\text{C}_2$ -C1P formation and stimulation of apoptosis (Graf et al., 2007). This controversy can be explained by the fact that overexpression of CerK would substantially increase the intracellular levels of C1P, especially when cells are supplied with high concentrations of exogenous cell permeable  $\text{C}_2$ -ceramide; this action would cause overproduction of  $\text{C}_2$ -C1P inside the cells, which is toxic at high concentrations (Gomez-Munoz et al., 1995a; Gomez-Munoz et al., 2004).

When cells become apoptotic, their metabolism undergoes important changes from early stages. For example, apoptotic bone marrow-derived macrophages express high acid sphingomyelinase (A-SMase) activity and show high levels of ceramides compared to non-apoptotic cells (Gomez-Munoz et al., 2003; Hundal et al., 2003). Of interest, inhibition of A-SMase activation resulted to be one of the mechanisms by which C1P blocks apoptosis (Gomez-Munoz et al., 2004). C1P also blocked the activity of A-SMase in cell-free systems (in vitro), suggesting that inhibition of this enzyme takes place by direct physical interaction of C1P with the enzyme.

Recent work by our group (Granado et al., 2009a) showed that ceramide levels are also increased in alveolar NR8383 macrophages when they become apoptotic. However, A-SMase activity was only slightly enhanced in these cells under apoptotic conditions. This suggested the intervention of a different pathway for ceramide generation in these cells. In subsequent work we demonstrated that the mechanism whereby ceramide levels increased in apoptotic alveolar macrophages involved activation of serine palmitoyltransferase (SPT), the key regulatory enzyme of the de novo pathway of ceramide synthesis. Like for A-SMase, inhibition of SPT activation by treatment with C1P prevented the alveolar macrophages from entering apoptosis. These findings led to conclude that C1P promotes macrophage survival by blocking ceramide accumulation, and action that can be brought about through inhibition of either A-SMase activity, or SPT, depending on cell type.

The prosurvival effect of C1P was highlighted by the demonstration that intracellular levels of C1P were substantially decreased when the cells became apoptotic. It was hypothesized

that depletion of intracellular C1P could result in the release of A-SMase from inhibition, thereby triggering ceramide generation and apoptotic cell death (Gomez-Munoz et al., 2004). Once generated, ceramides act on different intracellular targets to induce apoptosis. One of these targets is protein kinase B (or Akt), a kinase that lies downstream of PI3-K, a major signaling pathway through which growth factors promote cell survival. Using two different experimental approaches, it was demonstrated that PI3-K was also a target of C1P (Gomez-Munoz et al., 2005). On one hand, PI3-K activation was demonstrated by immunoprecipitation of the enzyme from whole cell lysates and assayed *in vitro* using <sup>32</sup>P-phosphatidylinositol. On the other hand, an *in vivo* approach provided evidence of phosphatidylinositol (3,4,5)-trisphosphate (PIP3) formation in intact cells that were prelabeled with <sup>32</sup>P-orthophosphate (Gomez-Munoz et al., 2005). PIP3 is a major product of PI3-K, and was shown to directly inhibit A-SMase (Testai et al., 2004). Therefore, it could be speculated that PI3-K activation might potentiate the inhibitory effect of C1P on A-SMase through generation of PIP3. C1P stimulated the phosphorylation of PKB, which was sensitive to inhibition by wortmannin or LY294002, thereby confirming that PI3-K was the enzyme responsible for its phosphorylation. These two PI3-K inhibitors also blocked the prosurvival effect of C1P, as expected (Gomez-Munoz et al., 2005). Another relevant finding was that C1P caused I $\kappa$ B phosphorylation and stimulation of the DNA binding activity of NF- $\kappa$ B in primary cultures of mouse macrophages (Gomez-Munoz et al., 2005). Of note, C1P up-regulated the expression of anti-apoptotic Bcl-XL, which is a downstream target of NF- $\kappa$ B. The latter results provided the first evidence for a novel biological role of natural C1P in the regulation of cell survival by the PI3-K/PKB/NF- $\kappa$ B pathway in mammalian cells (Gomez-Munoz et al., 2005).

As mentioned above, C1P can be metabolized to ceramide by different phosphatases, and then further converted to sphingosine and S1P by the coordinated actions of ceramidases and sphingosine kinases. Therefore, it could be speculated that the effects of C1P might be mediated through C1P-derived metabolites. However, usually ceramides and C1P exert opposing effects, (i.e. on PLD activation, adenylyl cyclase inhibition, or Ca<sup>2+</sup> mobilization), and C1P is not able to reproduce the effects of S1P (Gomez-Munoz et al., 1995a; Gomez-Munoz et al., 1995b; Gomez-Munoz et al., 1997; Gomez-Munoz, 1998). Also, ceramides can decrease the expression of Bcl-XL (Chalfant & Spiegel, 2005), whereas C1P causes its up-regulation (Gomez-Munoz et al., 2005). Finally, no ceramidases capable of converting C1P into S1P have so far been reported to exist in mammalian cells, and S1P and C1P inhibit A-SMase through different mechanisms (Gomez-Munoz et al., 2003; Gomez-Munoz et al., 2004). Therefore, it can be concluded that C1P acts on its own right to regulate cell homeostasis. The above observations suggest that regulation of the enzyme activities involved in ceramide and C1P metabolism is essential for cell fate. Elucidation of the mechanisms controlling ceramide and C1P levels may help develop new molecular strategies for preventing metabolic disorders, or designing novel therapeutic agents for treatment of disease.

## 5. Ceramide 1-phosphate and the control of inflammation

Inflammation is, in principle, a beneficial process for protecting the organism against infection or injury. However, it can be detrimental when it becomes out of control. Apart from the classical signaling pathways and metabolites that are involved in the regulation of

inflammation, it is now well accepted that ceramides are key elements in the inflammatory response (Lamour & Chalfant, 2005; Wijesinghe et al., 2008; Gomez-Munoz et al., 2010). For instance, it was reported that activation of A-SMase and the subsequent formation of ceramides play an important role in pulmonary infections as it facilitates internalization of bacteria into lung epithelial cells (Gulbins & Kolesnick, 2003). In this context, inhibition of A-SMase by C1P could be important to reduce or prevent infection in the lung.

Inflammatory mediators include chemokines, cytokines, vasoactive amines, products of proteolytic cascades, phospholipases, or lipids such as eicosanoids and sphingolipids. A major mediator of inflammation is PLA<sub>2</sub> activity. In particular, group IV cytosolic cPLA<sub>2</sub> (or cPLA<sub>2</sub>-alpha) has been involved in receptor-dependent and independent production of eicosanoids, which are major components of inflammatory responses. Sphingolipids, including ceramides, have also been described as key mediators of inflammation (Hayakawa et al., 1996; Serhan et al., 1996; Manna & Aggarwal, 1998; Newton et al., 2000). More recently a role for ceramide in the development of allergic asthmatic responses and airway inflammation was established (Masini et al., 2008), and exogenous addition of C<sub>2</sub>-ceramide to cultured astrocytes induced 12-lipoxygenase leading to generation of reactive oxygen species (ROS) and inflammation (Prasad et al., 2008). Also, A-SMase-derived ceramide was involved in platelet activating factor (PAF)-mediated pulmonary edema (Goggel et al., 2004). Subsequently, it was proposed that at least some of the pro-inflammatory effects of ceramides might in fact be mediated by its further metabolite C1P. The first report on the regulation of arachidonic acid (AA) release and the production of prostaglandins by C1P was from the laboratory of Charles Chalfant (Pettus et al., 2003b). This group demonstrated that C1P was able to stimulate AA release and prostanoid synthesis in A549 lung adenocarcinoma cells. In a follow up report, the same group showed that the mechanism whereby C1P stimulates AA release occurs through direct activation of cPLA<sub>2</sub> (Pettus et al., 2004). Subsequently, it was found that C1P is a positive allosteric activator of cPLA<sub>2</sub>-alpha, and that it enhances the interaction of the enzyme with PC (Subramanian et al., 2005). In further work, the same group demonstrated that activation of cPLA<sub>2</sub>-alpha by C1P is chain length-specific; in particular, C1P bearing acyl chains equal or higher than six carbons were able to efficiently activate cPLA<sub>2</sub>-alpha in vitro, whereas shorter acyl chains (in particular C<sub>2</sub>-C1P) were unable to activate the enzyme. It was concluded that the biological activity of C<sub>2</sub>-C1P does not occur via eicosanoid synthesis (Wijesinghe et al., 2008). Also, C1P was shown to act in coordination with S1P to ensure maximal production of prostaglandins. Specifically, S1P was shown to induce cyclooxygenase-2 (COX-2) activity, which then uses cPLA<sub>2</sub>-derived AA as substrate to synthesize prostaglandins (Pettus et al., 2005). Further details on the role of C1P in inflammatory response can be found in different reviews (Chalfant & Spiegel, 2005; Lamour et al., 2007; Wijesinghe et al., 2007), Wijesinghe et al., and recent work by Murayama and co-workers (Nakamura et al., 2011).

## 6. Ceramide 1-phosphate and the control of cell migration

Macrophage populations in tissues are determined by the rates of recruitment of monocytes from the bloodstream into the tissue, the rates of macrophage proliferation and apoptosis, and the rate of macrophage migration or efflux. Recently, our group demonstrated that exogenous addition of C1P to cultured Raw 264.7 macrophages stimulated cell migration

(Granado et al., 2009b). Interestingly, this action could only be observed when C1P was applied to the cells exogenously, and not by increasing the intracellular levels of C1P (i.e. through agonist stimulation of CerK, or by using the “caging” strategy to deliver C1P intracellularly (Lankalapalli et al., 2009)). This observation led us to identify a specific receptor through which C1P stimulates chemotaxis. This putative receptor seems to be located in the plasma membrane, has low affinity for C1P and has an apparent  $K_d$  of approximately 7.8  $\mu\text{M}$ . The receptor is specific for C1P and is coupled to  $G_i$  proteins. Ligation of this receptor with C1P caused phosphorylation of ERK1-2, and PKB, and inhibition of either of these pathways completely abolished C1P-stimulated macrophage migration. Moreover, C1P stimulated the DNA binding activity of NF- $\kappa$ B, and blockade of this transcription factor resulted in full inhibition of macrophage migration. These observations suggest that MEK/ERK1-2, PI3-K/PKB (or Akt) and NF- $\kappa$ B are crucial signaling pathways for regulation of cell migration by C1P. It was concluded that this newly identified receptor could be an important drug target for treatment of illnesses in which cell migration is a major cause of pathology, as it occurs in atherosclerosis or in the metastasis of tumors.

## 7. Other relevant biological actions of C1P

In a previous report, Hinkovska-Galcheva et al (Hinkovska-Galcheva et al., 1998) showed that endogenous C1P can be generated during the phagocytosis of antibody-coated erythrocytes in human neutrophils that were primed with formylmethionylleucylphenylalanine. More recently, the same group demonstrated that C1P is a key mediator of neutrophil phagocytosis (Hinkovska-Galcheva et al., 2005). In addition, it was reported that C1P can be formed in neutrophils upon incubation with cell-permeable [ $^3\text{H}$ ]N-hexanoylsphingosine ( $\text{C}_6$ -ceramide) (Rile et al., 2003), and Riboni and co-workers (Riboni et al., 2002) found that C1P can be generated in cerebellar granule cells both from SM-derived ceramide and through the recycling of sphingosine produced by ganglioside catabolism. C1P can be also generated by the action of interleukin 1-beta on A549 lung adenocarcinoma cells (Pettus et al., 2003b), or by stimulation of bone marrow-derived macrophages with macrophage-colony stimulating factor (M-CSF) (Gangoiti et al., 2008b). We found that C1P is present in normal bone marrow-derived macrophages isolated from healthy mice (Gomez-Munoz et al., 2004), and that C1P levels are substantially decreased in apoptotic macrophages. These observations are consistent with recent findings showing that CerK plays a key role in the stimulation of cell proliferation in A549 human lung adenocarcinoma cells (Mitra et al., 2007), and the induction of neointimal formation via cell proliferation and cell cycle progression in vascular smooth muscle cells by C1P (Kim et al., 2011).

## 8. Conclusion

The implication of simple sphingolipids in the regulation of cell activation and metabolism has acquired special relevance in the last two decades. Most attention was first paid to the effects elicited by ceramide because this sphingolipid turned out to be essential in the regulation of cell death, differentiation, senescence, and various metabolic disorders and diseases. However, its phosphorylated form, C1P, was thought not to be so important. However, C1P has emerged as a crucial bioactive sphingolipid, and this chapter highlights the relevance of C1P in cell biology. Specifically, C1P has now been established



as key regulator of cell growth and survival, and its relevance in the regulation of cell migration is beginning to emerge. Also importantly, the discovery that C1P can act both intracellularly or as receptor ligand opens a broad avenue to investigate its implication in controlling cell metabolism. In addition to this, C1P has been postulated to be a potent proinflammatory agent, acting directly on cPLA<sub>2</sub> to trigger eicosanoid production. Therefore, C1P and CerK, the major enzyme responsible for its biosynthesis, may be key targets for developing new pharmacological strategies for treatment of illnesses associated to cell growth and death, and cell migration, such as chronic inflammation, cardiovascular diseases, neurodegeneration, or cancer.

## 9. Acknowledgement

Work in AGM lab is supported by Ministerio de Ciencia e Innovación (Madrid, Spain), Departamento de Educación, Universidades e Investigación del Gobierno Vasco (Gazteiz-Vitoria, Basque Country), and Departamento de Industria, Comercio y Turismo del Gobierno Vasco (Gazteiz-Vitoria, Basque Country).

## 10. References

- Adams, J. M., 2nd, Pratipanawatr, T., Berria, R., Wang, E., DeFronzo, R. A., Sullards, M. C. and Mandarino, L. J. (2004). Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. *Diabetes* 53, 1,(Jan, 2004) 25-31, 0012-1797
- Arana, L., Gangoiti, P., Ouro, A., Trueba, M. and Gomez-Munoz, A. (2010). Ceramide and ceramide 1-phosphate in health and disease. *Lipids Health Dis* 9, 2010) 15, 1476-511X
- Bajjalieh, S. M., Martin, T. F. and Floor, E. (1989). Synaptic vesicle ceramide kinase. A calcium-stimulated lipid kinase that co-purifies with brain synaptic vesicles. *J Biol Chem* 264, 24,(Aug 25, 1989) 14354-60, 0021-9258
- Baumruker, T., Bornancin, F. and Billich, A. (2005). The role of sphingosine and ceramide kinases in inflammatory responses. *Immunol Lett* 96, 2,(Jan 31, 2005) 175-85, 0165-2478
- Bi, F. C., Zhang, Q. F., Liu, Z., Fang, C., Li, J., Su, J. B., Greenberg, J. T., Wang, H. B. and Yao, N. (2011). A conserved cysteine motif is critical for rice ceramide kinase activity and function. *PLoS One* 6, 3,(2011) e18079, 1932-6203
- Boath, A., Graf, C., Lidome, E., Ullrich, T., Nussbaumer, P. and Bornancin, F. (2008). Regulation and traffic of ceramide 1-phosphate produced by ceramide kinase: comparative analysis to glucosylceramide and sphingomyelin. *J Biol Chem* 283, 13,(Mar 28, 2008) 8517-26, 0021-9258
- Bornancin, F., Mechtcheriakova, D., Stora, S., Graf, C., Wlachos, A., Devay, P., Urtz, N., Baumruker, T. and Billich, A. (2005). Characterization of a ceramide kinase-like protein. *Biochim Biophys Acta* 1687, 1-3,(Feb 21, 2005) 31-43, 0005-2736
- Boudker, O. and Futerman, A. H. (1993). Detection and characterization of ceramide-1-phosphate phosphatase activity in rat liver plasma membrane. *J Biol Chem* 268, 29,(Oct 15, 1993) 22150-5, 0021-9258
- Brann, A. B., Scott, R., Neuberger, Y., Abulafia, D., Boldin, S., Fainzilber, M. and Futerman, A. H. (1999). Ceramide signaling downstream of the p75 neurotrophin receptor mediates the effects of nerve growth factor on outgrowth of cultured hippocampal neurons. *J Neurosci* 19, 19,(Oct 1, 1999) 8199-206, 0270-6474



- Brindley, D. N. and Waggoner, D. W. (1998). Mammalian lipid phosphate phosphohydrolases. *J Biol Chem* 273, 38,(Sep 18, 1998) 24281-4, 0021-9258
- Brizuela, L., Rabano, M., Pena, A., Gangoiti, P., Macarulla, J. M., Trueba, M. and Gomez-Munoz, A. (2006). Sphingosine 1-phosphate: a novel stimulator of aldosterone secretion. *J Lipid Res* 47, 6,(Jun, 2006) 1238-49, 0022-2275
- Colina, C., Flores, A., Castillo, C., Garrido Mdel, R., Israel, A., DiPolo, R. and Benaim, G. (2005). Ceramide-1-P induces Ca<sup>2+</sup> mobilization in Jurkat T-cells by elevation of Ins(1,4,5)-P<sub>3</sub> and activation of a store-operated calcium channel. *Biochem Biophys Res Commun* 336, 1,(Oct 14, 2005) 54-60, 0006-291X
- Chalfant, C. E. and Spiegel, S. (2005). Sphingosine 1-phosphate and ceramide 1-phosphate: expanding roles in cell signaling. *J Cell Sci* 118, Pt 20,(Oct 15, 2005) 4605-12, 0021-9533
- Chen, Y., Liu, Y., Sullards, M. C. and Merrill, A. H., Jr. (2011). An introduction to sphingolipid metabolism and analysis by new technologies. *Neuromolecular Med* 12, 4,(Dec, 2011) 306-19, 1535-1084
- Dressler, K. A., Mathias, S. and Kolesnick, R. N. (1992). Tumor necrosis factor-alpha activates the sphingomyelin signal transduction pathway in a cell-free system. *Science* 255, 5052,(Mar 27, 1992) 1715-8, 0036-8075
- Gangoiti, P., Arana, L., Ouro, A., Granado, M. H., Trueba, M. and Gomez-Munoz, A. (2010a). Activation of mTOR and RhoA is a major mechanism by which Ceramide 1-phosphate stimulates macrophage proliferation. *Cell Signal* 23, 1,(Aug 18, 2010a) 27-34,
- Gangoiti, P., Camacho, L., Arana, L., Ouro, A., Granado, M. H., Brizuela, L., Casas, J., Fabrias, G., Abad, J. L., Delgado, A. and Gomez-Munoz, A. (2010b). Control of metabolism and signaling of simple bioactive sphingolipids: Implications in disease. *Prog Lipid Res* 49, 4,(Oct, 2010b) 316-34, 0163-7827
- Gangoiti, P., Granado, M. H., Alonso, A., Goñi, F. M. and Gómez-Muñoz, A. (2008a). Implication of Ceramide, Ceramide 1-Phosphate and Sphingosine 1-Phosphate in Tumorigenesis. *Translational Oncogenomics* 3 2008a) 67-79, 1177-2727
- Gangoiti, P., Granado, M. H., Arana, L., Ouro, A. and Gomez-Munoz, A. (2010c). Activation of protein kinase C-alpha is essential for stimulation of cell proliferation by ceramide 1-phosphate. *FEBS Lett* 584, 3,(Feb 5, 2010c) 517-24, 0014-5793
- Gangoiti, P., Granado, M. H., Wang, S. W., Kong, J. Y., Steinbrecher, U. P. and Gomez-Munoz, A. (2008b). Ceramide 1-phosphate stimulates macrophage proliferation through activation of the PI3-kinase/PKB, JNK and ERK1/2 pathways. *Cell Signal* 20, 4,(Apr, 2008b) 726-36, 0898-6568
- Gijsbers, S., Mannaerts, G. P., Himpens, B. and Van Veldhoven, P. P. (1999). N-acetyl-sphingenine-1-phosphate is a potent calcium mobilizing agent. *FEBS Lett* 453, 3,(Jun 25, 1999) 269-72, 0014-5793
- Goggel, R., Winoto-Morbach, S., Vielhaber, G., Imai, Y., Lindner, K., Brade, L., Brade, H., Ehlers, S., Slutsky, A. S., Schutze, S., Gulbins, E. and Uhlig, S. (2004). PAF-mediated pulmonary edema: a new role for acid sphingomyelinase and ceramide. *Nat Med* 10, 2,(Feb, 2004) 155-60, 1078-8956
- Gomez-Munoz, A. (1998). Modulation of cell signalling by ceramides. *Biochim Biophys Acta* 1391, 1,(Mar 6, 1998) 92-109, 0005-2736
- Gomez-Munoz, A. (2004). Ceramide-1-phosphate: a novel regulator of cell activation. *FEBS Lett* 562, 1-3,(Mar 26, 2004) 5-10, 0014-5793

- Gomez-Munoz, A. (2006). Ceramide 1-phosphate/ceramide, a switch between life and death. *Biochim Biophys Acta* 1758, 12,(Dec, 2006) 2049-56, 0005-2736
- Gomez-Munoz, A., Duffy, P. A., Martin, A., O'Brien, L., Byun, H. S., Bittman, R. and Brindley, D. N. (1995a). Short-chain ceramide-1-phosphates are novel stimulators of DNA synthesis and cell division: antagonism by cell-permeable ceramides. *Mol Pharmacol* 47, 5,(May, 1995a) 833-9, 0026-895X
- Gomez-Munoz, A., Frago, L. M., Alvarez, L. and Varela-Nieto, I. (1997). Stimulation of DNA synthesis by natural ceramide 1-phosphate. *Biochem J* 325 ( Pt 2), Jul 15, 1997) 435-40, 0264-6021
- Gomez-Munoz, A., Gangoiti, P., Granado, M. H., Arana, L. and Ouro, A. (2010). Ceramide 1-Phosphate in Cell Survival and Inflammatory Signaling. Sphingolipids as Signaling and Regulatory Molecules. C. Chalfant and M. D. Poeta. Austin (Tx), Landes Bioscience and Springer Science+Business Media: 118-130.
- Gomez-Munoz, A., Hamza, E. H. and Brindley, D. N. (1992). Effects of sphingosine, albumin and unsaturated fatty acids on the activation and translocation of phosphatidate phosphohydrolases in rat hepatocytes. *Biochim Biophys Acta* 1127, 1,(Jul 9, 1992) 49-56, 0005-2736
- Gomez-Munoz, A., Kong, J., Salh, B. and Steinbrecher, U. P. (2003). Sphingosine-1-phosphate inhibits acid sphingomyelinase and blocks apoptosis in macrophages. *FEBS Lett* 539, 1-3,(Mar 27, 2003) 56-60, 0014-5793
- Gomez-Munoz, A., Kong, J. Y., Parhar, K., Wang, S. W., Gangoiti, P., Gonzalez, M., Eivemark, S., Salh, B., Duronio, V. and Steinbrecher, U. P. (2005). Ceramide-1-phosphate promotes cell survival through activation of the phosphatidylinositol 3-kinase/protein kinase B pathway. *FEBS Lett* 579, 17,(Jul 4, 2005) 3744-50, 1177-5793
- Gomez-Munoz, A., Kong, J. Y., Salh, B. and Steinbrecher, U. P. (2004). Ceramide-1-phosphate blocks apoptosis through inhibition of acid sphingomyelinase in macrophages. *J Lipid Res* 45, 1,(Jan, 2004) 99-105, 0022-2275
- Gomez-Munoz, A., Waggoner, D. W., O'Brien, L. and Brindley, D. N. (1995b). Interaction of ceramides, sphingosine, and sphingosine 1-phosphate in regulating DNA synthesis and phospholipase D activity. *J Biol Chem* 270, 44,(Nov 3, 1995b) 26318-25, 0022-2275
- Goodman, Y. and Mattson, M. P. (1996). Ceramide protects hippocampal neurons against excitotoxic and oxidative insults, and amyloid beta-peptide toxicity. *J Neurochem* 66, 2,(Feb, 1996) 869-72, 0022-3042
- Graf, C., Rovina, P., Tauzin, L., Schanzer, A. and Bornancin, F. (2007). Enhanced ceramide-induced apoptosis in ceramide kinase overexpressing cells. *Biochem Biophys Res Commun* 354, 1,(Mar 2, 2007) 309-14, 0006-291X
- Graf, C., Zemann, B., Rovina, P., Urtz, N., Schanzer, A., Reuschel, R., Mechtcheriakova, D., Muller, M., Fischer, E., Reichel, C., Huber, S., Dawson, J., Meingassner, J. G., Billich, A., Niwa, S., Badegruber, R., Van Veldhoven, P. P., Kinzel, B., Baumruker, T. and Bornancin, F. (2008). Neutropenia with Impaired Immune Response to *Streptococcus pneumoniae* in Ceramide Kinase-Deficient Mice. *J Immunol* 180, 5,(Mar 1, 2008) 3457-66, 0022-1767
- Granado, M. H., Gangoiti, P., Ouro, A., Arana, L. and Gomez-Munoz, A. (2009a). Ceramide 1-phosphate inhibits serine palmitoyltransferase and blocks apoptosis in alveolar macrophages. *Biochim Biophys Acta* 1791, 4,(Apr, 2009a) 263-72, 0005-2736

- Granado, M. H., Gangoiti, P., Ouro, A., Arana, L., Gonzalez, M., Trueba, M. and Gomez-Munoz, A. (2009b). Ceramide 1-phosphate (C1P) promotes cell migration Involvement of a specific C1P receptor. *Cell Signal* 21, 3,(Mar, 2009b) 405-12, 0898-6568
- Gulbins, E. and Kolesnick, R. (2003). Raft ceramide in molecular medicine. *Oncogene* 22, 45,(Oct 13, 2003) 7070-7, 0950-9232
- Hannun, Y. A. (1994). The sphingomyelin cycle and the second messenger function of ceramide. *J Biol Chem* 269, 5,(Feb 4, 1994) 3125-8, 0021-9258
- Hannun, Y. A. (1996). Functions of ceramide in coordinating cellular responses to stress. *Science* 274, 5294,(Dec 13, 1996) 1855-9,
- Hannun, Y. A., Loomis, C. R., Merrill, A. H., Jr. and Bell, R. M. (1986). Sphingosine inhibition of protein kinase C activity and of phorbol dibutyrate binding in vitro and in human platelets. *J Biol Chem* 261, 27,(Sep 25, 1986) 12604-9, 0021-9258
- Hannun, Y. A. and Obeid, L. M. (1995). Ceramide: an intracellular signal for apoptosis. *Trends Biochem Sci* 20, 2,(Feb, 1995) 73-7, 0968-0004
- Hannun, Y. A. and Obeid, L. M. (2002). The Ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. *J Biol Chem* 277, 29,(Jul 19, 2002) 25847-50,
- Hannun, Y. A. and Obeid, L. M. (2008). Principles of bioactive lipid signalling: lessons from sphingolipids. *Nat Rev Mol Cell Biol* 9, 2,(Feb, 2008) 139-50, 0028-0836
- Hannun, Y. A. and Obeid, L. M. (2011). Many ceramides. *J Biol Chem* 286, 32,(Aug 12, 2011) 27855-62, 0021-9258
- Hayakawa, M., Jayadev, S., Tsujimoto, M., Hannun, Y. A. and Ito, F. (1996). Role of ceramide in stimulation of the transcription of cytosolic phospholipase A2 and cyclooxygenase 2. *Biochem Biophys Res Commun* 220, 3,(Mar 27, 1996) 681-6, 0006-291X
- Hinkovska-Galcheva, V., Boxer, L. A., Kindzelskii, A., Hiraoka, M., Abe, A., Goparju, S., Spiegel, S., Petty, H. R. and Shayman, J. A. (2005). Ceramide 1-phosphate, a mediator of phagocytosis. *J Biol Chem* 280, 28,(Jul 15, 2005) 26612-21, 0021-9258
- Hinkovska-Galcheva, V. and Shayman, J. A. Ceramide-1-phosphate in phagocytosis and calcium homeostasis. *Adv Exp Med Biol* 688, 131-40, 0065-2598
- Hinkovska-Galcheva, V. T., Boxer, L. A., Mansfield, P. J., Harsh, D., Blackwood, A. and Shayman, J. A. (1998). The formation of ceramide-1-phosphate during neutrophil phagocytosis and its role in liposome fusion. *J Biol Chem* 273, 50,(Dec 11, 1998) 33203-9, 0021-9258
- Hogback, S., Leppimaki, P., Rudnas, B., Bjorklund, S., Slotte, J. P. and Tornquist, K. (2003). Ceramide 1-phosphate increases intracellular free calcium concentrations in thyroid FRTL-5 cells: evidence for an effect mediated by inositol 1,4,5-trisphosphate and intracellular sphingosine 1-phosphate. *Biochem J* 370, Pt 1,(Feb 15, 2003) 111-9, 0264-6021
- Holland, W. L., Bikman, B. T., Wang, L. P., Yuguang, G., Sargent, K. M., Bulchand, S., Knotts, T. A., Shui, G., Clegg, D. J., Wenk, M. R., Pagliassotti, M. J., Scherer, P. E. and Summers, S. A. (2011). Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice. *J Clin Invest* 121, 5,(May 2, 2011) 1858-70, 0021-9738

- Hundal, R. S., Gomez-Munoz, A., Kong, J. Y., Salh, B. S., Marotta, A., Duronio, V. and Steinbrecher, U. P. (2003). Oxidized low density lipoprotein inhibits macrophage apoptosis by blocking ceramide generation, thereby maintaining protein kinase B activation and Bcl-XL levels. *J Biol Chem* 278, 27,(Jul 4, 2003) 24399-408, 0022-9258
- Jamal, Z., Martin, A., Gomez-Munoz, A. and Brindley, D. N. (1991). Plasma membrane fractions from rat liver contain a phosphatidate phosphohydrolase distinct from that in the endoplasmic reticulum and cytosol. *J Biol Chem* 266, 5,(Feb 15, 1991) 2988-96, 0021-9258
- Kim, T. J., Kang, Y. J., Lim, Y., Lee, H. W., Bae, K., Lee, Y. S., Yoo, J. M., Yoo, H. S. and Yun, Y. P. (2011). Ceramide 1-phosphate induces neointimal formation via cell proliferation and cell cycle progression upstream of ERK1/2 in vascular smooth muscle cells. *Exp Cell Res* 317, 14,(Aug 15, 2011) 2041-51, 0014-4827
- Kim, T. J., Mitsutake, S. and Igarashi, Y. (2006). The interaction between the pleckstrin homology domain of ceramide kinase and phosphatidylinositol 4,5-bisphosphate regulates the plasma membrane targeting and ceramide 1-phosphate levels. *Biochem Biophys Res Commun* 342, 2,(Apr 7, 2006) 611-7, 0006-291X
- Kim, T. J., Mitsutake, S., Kato, M. and Igarashi, Y. (2005). The leucine 10 residue in the pleckstrin homology domain of ceramide kinase is crucial for its catalytic activity. *FEBS Lett* 579, 20,(Aug 15, 2005) 4383-8, 0014-5793
- Kolesnick, R. and Golde, D. W. (1994). The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signaling. *Cell* 77, 3,(May 6, 1994) 325-8, 0272-4340
- Kolesnick, R. N. (1987). 1,2-Diacylglycerols but not phorbol esters stimulate sphingomyelin hydrolysis in GH3 pituitary cells. *J Biol Chem* 262, 35,(Dec 15, 1987) 16759-62, 0021-9258
- Kolesnick, R. N., Goni, F. M. and Alonso, A. (2000). Compartmentalization of ceramide signaling: physical foundations and biological effects. *J Cell Physiol* 184, 3,(Sep, 2000) 285-300, 0021-9541
- Kolesnick, R. N. and Hemer, M. R. (1990). Characterization of a ceramide kinase activity from human leukemia (HL-60) cells. Separation from diacylglycerol kinase activity. *J Biol Chem* 265, 31,(Nov 5, 1990) 18803-8, 0021-9258
- Lamour, N. F. and Chalfant, C. E. (2005). Ceramide-1-phosphate: the "missing" link in eicosanoid biosynthesis and inflammation. *Mol Interv* 5, 6,(Dec, 2005) 358-67, 1543-2548
- Lamour, N. F., Stahelin, R. V., Wijesinghe, D. S., Maceyka, M., Wang, E., Allegood, J. C., Merrill, A. H., Jr., Cho, W. and Chalfant, C. E. (2007). Ceramide kinase uses ceramide provided by ceramide transport protein: localization to organelles of eicosanoid synthesis. *J Lipid Res* 48, 6,(Jun, 2007) 1293-304, 0022-2275
- Lankalapalli, R. S., Ouro, A., Arana, L., Gomez-Munoz, A. and Bittman, R. (2009). Caged ceramide 1-phosphate analogues: synthesis and properties. *J Org Chem* 74, 22,(Nov 20, 2009) 8844-7, 5163-5166
- Lee, S. and Lynch, K. R. (2005). Brown recluse spider (*Loxosceles reclusa*) venom phospholipase D (PLD) generates lysophosphatidic acid (LPA). *Biochem J* 391, Pt 2,(Oct 15, 2005) 317-23, 0264-6021
- Long, J., Darroch, P., Wan, K. F., Kong, K. C., Ktistakis, N., Pyne, N. J. and Pyne, S. (2005). Regulation of cell survival by lipid phosphate phosphatases involves the




- modulation of intracellular phosphatidic acid and sphingosine 1-phosphate pools. *Biochem J* 391, Pt 1,(Oct 1, 2005) 25-32, 0264-6021
- Manna, S. K. and Aggarwal, B. B. (1998). IL-13 suppresses TNF-induced activation of nuclear factor-kappa B, activation protein-1, and apoptosis. *J Immunol* 161, 6,(Sep 15, 1998) 2863-72, 0022-1767
- Masini, E., Giannini, L., Nistri, S., Cinci, L., Mastroianni, R., Xu, W., Comhair, S. A., Li, D., Cuzzocrea, S., Matuschak, G. M. and Salvemini, D. (2008). Ceramide: a key signaling molecule in a Guinea pig model of allergic asthmatic response and airway inflammation. *J Pharmacol Exp Ther* 324, 2,(Feb, 2008) 548-57., 0022-3565
- Mathias, S., Dressler, K. A. and Kolesnick, R. N. (1991). Characterization of a ceramide-activated protein kinase: stimulation by tumor necrosis factor alpha. *Proc Natl Acad Sci U S A* 88, 22,(Nov 15, 1991) 10009-13, 1091-6490
- Menaldino, D. S., Bushnev, A., Sun, A., Liotta, D. C., Symolon, H., Desai, K., Dillehay, D. L., Peng, Q., Wang, E., Allegood, J., Trotman-Pruett, S., Sullards, M. C. and Merrill, A. H., Jr. (2003). Sphingoid bases and de novo ceramide synthesis: enzymes involved, pharmacology and mechanisms of action. *Pharmacol Res* 47, 5,(May, 2003) 373-81, 1043-6618
- Merrill, A. H., Jr. (1991). Cell regulation by sphingosine and more complex sphingolipids. *J Bioenerg Biomembr* 23, 1,(Feb, 1991) 83-104, 0145-479X
- Merrill, A. H., Jr. (2002). De novo sphingolipid biosynthesis: a necessary, but dangerous, pathway. *J Biol Chem* 277, 29,(Jul 19, 2002) 25843-6, 0021-9258
- Merrill, A. H., Jr. and Jones, D. D. (1990). An update of the enzymology and regulation of sphingomyelin metabolism. *Biochim Biophys Acta* 1044, 1,(May 1, 1990) 1-12, 0005-2736
- Merrill, A. H., Jr., Schmelz, E. M., Dillehay, D. L., Spiegel, S., Shayman, J. A., Schroeder, J. J., Riley, R. T., Voss, K. A. and Wang, E. (1997). Sphingolipids--the enigmatic lipid class: biochemistry, physiology, and pathophysiology. *Toxicol Appl Pharmacol* 142, 1,(Jan, 1997) 208-25, 0041-008X
- Merrill, A. H., Jr., Sullards, M. C., Allegood, J. C., Kelly, S. and Wang, E. (2005). Sphingolipidomics: high-throughput, structure-specific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry. *Methods* 36, 2,(Jun, 2005) 207-24, 1548-7091
- Merrill, A. H., Jr., Sullards, M. C., Wang, E., Voss, K. A. and Riley, R. T. (2001). Sphingolipid metabolism: roles in signal transduction and disruption by fumonisins. *Environ Health Perspect* 109 Suppl 2, May, 2001) 283-9, 0091-6765
- Miranda, G. E., Abraham, C. E., Agnolazza, D. L., Politi, L. E. and Rotstein, N. P. (2011). Ceramide-1-phosphate, a new mediator of development and survival in retina photoreceptors. *Invest Ophthalmol Vis Sci* 52, 9,(2011) 6580-8, 1552-5783
- Mitra, P., Maceyka, M., Payne, S. G., Lamour, N., Milstien, S., Chalfant, C. E. and Spiegel, S. (2007). Ceramide kinase regulates growth and survival of A549 human lung adenocarcinoma cells. *FEBS Lett* 581, 4,(Feb 20, 2007) 735-40, 0014-5793
- Mitsutake, S., Kim, T. J., Inagaki, Y., Kato, M., Yamashita, T. and Igarashi, Y. (2004). Ceramide kinase is a mediator of calcium-dependent degranulation in mast cells. *J Biol Chem* 279, 17,(Apr 23, 2004) 17570-7, 0021-9258
- Nakamura, H., Tada, E., Makiyama, T., Yasufuku, K. and Murayama, T. (2011). Role of cytosolic phospholipase A(2)alpha in cell rounding and cytotoxicity induced by



- ceramide-1-phosphate via ceramide kinase. *Arch Biochem Biophys* 512, 1,(Aug 1, 2011) 45-51, 0003-9861
- Natarajan, V., Jayaram, H. N., Scribner, W. M. and Garcia, J. G. (1994). Activation of endothelial cell phospholipase D by sphingosine and sphingosine-1-phosphate. *Am J Respir Cell Mol Biol* 11, 2,(Aug, 1994) 221-9, 1044-1549
- Newton, R., Hart, L., Chung, K. F. and Barnes, P. J. (2000). Ceramide induction of COX-2 and PGE(2) in pulmonary A549 cells does not involve activation of NF-kappaB. *Biochem Biophys Res Commun* 277, 3,(Nov 2, 2000) 675-9, 0006-291X
- Okazaki, T., Bielawska, A., Bell, R. M. and Hannun, Y. A. (1990). Role of ceramide as a lipid mediator of 1 alpha,25-dihydroxyvitamin D3-induced HL-60 cell differentiation. *J Biol Chem* 265, 26,(Sep 15, 1990) 15823-31, 0021-9258
- Olivera, A. and Spiegel, S. (1993). Sphingosine-1-phosphate as second messenger in cell proliferation induced by PDGF and FCS mitogens. *Nature* 365, 6446,(Oct 7, 1993) 557-60, 0028-0836
- Pettus, B. J., Bielawska, A., Kroesen, B. J., Moeller, P. D., Szulc, Z. M., Hannun, Y. A. and Busman, M. (2003a). Observation of different ceramide species from crude cellular extracts by normal-phase high-performance liquid chromatography coupled to atmospheric pressure chemical ionization mass spectrometry. *Rapid Commun Mass Spectrom* 17, 11,(2003a) 1203-11, 0951-4198
- Pettus, B. J., Bielawska, A., Spiegel, S., Roddy, P., Hannun, Y. A. and Chalfant, C. E. (2003b). Ceramide kinase mediates cytokine- and calcium ionophore-induced arachidonic acid release. *J Biol Chem* 278, 40,(Oct 3, 2003b) 38206-13, 0022-9258
- Pettus, B. J., Bielawska, A., Subramanian, P., Wijesinghe, D. S., Maceyka, M., Leslie, C. C., Evans, J. H., Freiberg, J., Roddy, P., Hannun, Y. A. and Chalfant, C. E. (2004). Ceramide 1-phosphate is a direct activator of cytosolic phospholipase A2. *J Biol Chem* 279, 12,(Mar 19, 2004) 11320-6, 0021-9258
- Pettus, B. J., Kitatani, K., Chalfant, C. E., Taha, T. A., Kawamori, T., Bielawski, J., Obeid, L. M. and Hannun, Y. A. (2005). The coordination of prostaglandin E2 production by sphingosine-1-phosphate and ceramide-1-phosphate. *Mol Pharmacol* 68, 2,(Aug, 2005) 330-5, 0026-895X
- Ping, S. E. and Barrett, G. L. (1998). Ceramide can induce cell death in sensory neurons, whereas ceramide analogues and sphingosine promote survival. *J Neurosci Res* 54, 2,(Oct 15, 1998) 206-13, 1097-4547
- Plummer, G., Perreault, K. R., Holmes, C. F. and Posse De Chaves, E. I. (2005). Activation of serine/threonine protein phosphatase-1 is required for ceramide-induced survival of sympathetic neurons. *Biochem J* 385, Pt 3,(Feb 1, 2005) 685-93, 0264-6021
- Prasad, V. V., Nithipatikom, K. and Harder, D. R. (2008). Ceramide elevates 12-hydroxyeicosatetraenoic acid levels and upregulates 12-lipoxygenase in rat primary hippocampal cell cultures containing predominantly astrocytes. *Neurochem Int* 53, 6-8,(Nov-Dec, 2008) 220-9, 0197-0186
- Rabano, M., Pena, A., Brizuela, L., Marino, A., Macarulla, J. M., Trueba, M. and Gomez-Munoz, A. (2003). Sphingosine-1-phosphate stimulates cortisol secretion. *FEBS Lett* 535, 1-3,(Jan 30, 2003) 101-5, 0014-5793
- Riboni, L., Bassi, R., Anelli, V. and Viani, P. (2002). Metabolic formation of ceramide-1-phosphate in cerebellar granule cells: evidence for the phosphorylation of ceramide by different metabolic pathways. *Neurochem Res* 27, 7-8,(Aug, 2002) 711-6, 0364-3190

- Rile, G., Yatomi, Y., Takafuta, T. and Ozaki, Y. (2003). Ceramide 1-phosphate formation in neutrophils. *Acta Haematol* 109, 2,(2003) 76-83, 0001-5792
- Rovina, P., Graf, C. and Bornancin, F. (2010). Modulation of ceramide metabolism in mouse primary macrophages. *Biochem Biophys Res Commun* 399, 2,(Aug 20, 2010) 150-4, 0006-291X
- Sakane, F., Yamada, K. and Kanoh, H. (1989). Different effects of sphingosine, R59022 and anionic amphiphiles on two diacylglycerol kinase isozymes purified from porcine thymus cytosol. *FEBS Lett* 255, 2,(Sep 25, 1989) 409-13, 0014-5793
- Schmitz-Peiffer, C. (2002). Protein kinase C and lipid-induced insulin resistance in skeletal muscle. *Ann N Y Acad Sci* 967, Jun, 2002) 146-57, 0077-8923
- Serhan, C. N., Haeggstrom, J. Z. and Leslie, C. C. (1996). Lipid mediator networks in cell signaling: update and impact of cytokines. *Faseb J* 10, 10,(Aug, 1996) 1147-58, 0892-6638
- Shinghal, R., Scheller, R. H. and Bajjalieh, S. M. (1993). Ceramide 1-phosphate phosphatase activity in brain. *J Neurochem* 61, 6,(Dec, 1993) 2279-85, 0022-3042
- Smith, E. R., Jones, P. L., Boss, J. M. and Merrill, A. H., Jr. (1997). Changing J774A.1 cells to new medium perturbs multiple signaling pathways, including the modulation of protein kinase C by endogenous sphingoid bases. *J Biol Chem* 272, 9,(Feb 28, 1997) 5640-6, 0021-9258
- Song, M. S. and Posse de Chaves, E. I. (2003). Inhibition of rat sympathetic neuron apoptosis by ceramide. Role of p75NTR in ceramide generation. *Neuropharmacology* 45, 8,(Dec, 2003) 1130-50, 0028-3908
- Spiegel, S., Foster, D. and Kolesnick, R. (1996). Signal transduction through lipid second messengers. *Curr Opin Cell Biol* 8, 2,(Apr, 1996) 159-67, 0955-0674
- Spiegel, S. and Merrill, A. H., Jr. (1996). Sphingolipid metabolism and cell growth regulation. *Faseb J* 10, 12,(Oct, 1996) 1388-97,
- Spiegel, S. and Milstien, S. (2002). Sphingosine 1-phosphate, a key cell signaling molecule. *J Biol Chem* 277, 29,(Jul 19, 2002) 25851-4, 0021-9258
- Spiegel, S. and Milstien, S. (2003). Sphingosine-1-phosphate: an enigmatic signalling lipid. *Nat Rev Mol Cell Biol* 4, 5,(May, 2003) 397-407, 1471-0072
- Stratford, S., Hoehn, K. L., Liu, F. and Summers, S. A. (2004). Regulation of insulin action by ceramide: dual mechanisms linking ceramide accumulation to the inhibition of Akt/protein kinase B. *J Biol Chem* 279, 35,(Aug 27, 2004) 36608-15, 0021-9258
- Subramanian, P., Stahelin, R. V., Szulc, Z., Bielawska, A., Cho, W. and Chalfant, C. E. (2005). Ceramide 1-phosphate acts as a positive allosteric activator of group IVA cytosolic phospholipase A2 alpha and enhances the interaction of the enzyme with phosphatidylcholine. *J Biol Chem* 280, 18,(May 6, 2005) 17601-7, 0021-9258
- Sugiura, M., Kono, K., Liu, H., Shimizugawa, T., Minekura, H., Spiegel, S. and Kohama, T. (2002). Ceramide kinase, a novel lipid kinase. Molecular cloning and functional characterization. *J Biol Chem* 277, 26,(Jun 28, 2002) 23294-300, 0021-9258
- Tada, E., Toyomura, K., Nakamura, H., Sasaki, H., Saito, T., Kaneko, M., Okuma, Y. and Murayama, T. (2010). Activation of ceramidase and ceramide kinase by vanadate via a tyrosine kinase-mediated pathway. *J Pharmacol Sci* 114, 4,(2010) 420-32, 1347-8613
- Testai, F. D., Landek, M. A., Goswami, R., Ahmed, M. and Dawson, G. (2004). Acid sphingomyelinase and inhibition by phosphate ion: role of inhibition by

- phosphatidyl-myo-inositol 3,4,5-triphosphate in oligodendrocyte cell signaling. *J Neurochem* 89, 3,(May, 2004) 636-44, 0022-3042
- Truett, A. P., 3rd and King, L. E., Jr. (1993). Sphingomyelinase D: a pathogenic agent produced by bacteria and arthropods. *Adv Lipid Res* 26, 1993) 275-91, 0065-2849
- Tuson, M., Marfany, G. and Gonzalez-Duarte, R. (2004). Mutation of CERKL, a novel human ceramide kinase gene, causes autosomal recessive retinitis pigmentosa (RP26). *Am J Hum Genet* 74, 1,(Jan, 2004) 128-38, 0002-9297
- Van Overloop, H., Denizot, Y., Baes, M. and Van Veldhoven, P. P. (2007). On the presence of C2-ceramide in mammalian tissues: possible relationship to etherphospholipids and phosphorylation by ceramide kinase. *Biol Chem* 388, 3,(Mar, 2007) 315-24, 0264-6021
- Van Overloop, H., Gijbbers, S. and Van Veldhoven, P. P. (2006). Further characterization of mammalian ceramide kinase: substrate delivery and (stereo)specificity, tissue distribution, and subcellular localization studies. *J Lipid Res* 47, 2,(Feb, 2006) 268-83, 0022-2275
- Waggoner, D. W., Gomez-Munoz, A., Dewald, J. and Brindley, D. N. (1996). Phosphatidate phosphohydrolase catalyzes the hydrolysis of ceramide 1-phosphate, lysophosphatidate, and sphingosine 1-phosphate. *J Biol Chem* 271, 28,(Jul 12, 1996) 16506-9, 0021-9258
- Wijesinghe, D. S., Lamour, N. F., Gomez-Munoz, A. and Chalfant, C. E. (2007). Ceramide kinase and ceramide-1-phosphate. *Methods Enzymol* 434, 2007) 265-92, 0076-6879
- Wijesinghe, D. S., Massiello, A., Subramanian, P., Szulc, Z., Bielawska, A. and Chalfant, C. E. (2005). Substrate specificity of human ceramide kinase. *J Lipid Res* 46, 12,(Dec, 2005) 2706-16, 0022-2275
- Wijesinghe, D. S., Subramanian, P., Lamour, N. F., Gentile, L. B., Granado, M. H., Szulc, Z., Bielawska, A., Gomez-Munoz, A. and Chalfant, C. E. (2008). The chain length specificity for the activation of group IV cytosolic phospholipase A2 by ceramide-1-phosphate. Use of the dodecane delivery system for determining lipid-specific effects. *J Lipid Res* 49, 10,(Dec 15, 2008) 1986-95, 0022-2275
- Wu, J., Spiegel, S. and Sturgill, T. W. (1995). Sphingosine 1-phosphate rapidly activates the mitogen-activated protein kinase pathway by a G protein-dependent mechanism. *J Biol Chem* 270, 19,(May 12, 1995) 11484-8, 0021-9258
- Yamada, K., Sakane, F., Imai, S. and Takemura, H. (1993). Sphingosine activates cellular diacylglycerol kinase in intact Jurkat cells, a human T-cell line. *Biochim Biophys Acta* 1169, 3,(Sep 8, 1993) 217-24, 0005-2736
- Zhao, Y., Usatyuk, P. V., Cummings, R., Saatian, B., He, D., Watkins, T., Morris, A., Spannhake, E. W., Brindley, D. N. and Natarajan, V. (2005). Lipid phosphate phosphatase-1 regulates lysophosphatidic acid-induced calcium release, NF-kappaB activation and interleukin-8 secretion in human bronchial epithelial cells. *Biochem J* 385, Pt 2,(Jan 15, 2005) 493-502, 0264-6021



## **Biochemistry**

Edited by Prof. Deniz Ekinci

ISBN 978-953-51-0076-8

Hard cover, 452 pages

**Publisher** InTech

**Published online** 02, March, 2012

**Published in print edition** March, 2012

Over the recent years, biochemistry has become responsible for explaining living processes such that many scientists in the life sciences from agronomy to medicine are engaged in biochemical research. This book contains an overview focusing on the research area of proteins, enzymes, cellular mechanisms and chemical compounds used in relevant approaches. The book deals with basic issues and some of the recent developments in biochemistry. Particular emphasis is devoted to both theoretical and experimental aspect of modern biochemistry. The primary target audience for the book includes students, researchers, biologists, chemists, chemical engineers and professionals who are interested in biochemistry, molecular biology and associated areas. The book is written by international scientists with expertise in protein biochemistry, enzymology, molecular biology and genetics many of which are active in biochemical and biomedical research. We hope that the book will enhance the knowledge of scientists in the complexities of some biochemical approaches; it will stimulate both professionals and students to dedicate part of their future research in understanding relevant mechanisms and applications of biochemistry.

### **How to reference**

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Alberto Ouro, Lide Arana, Patricia Gangoiti and Antonio Gomez-Muñoz (2012). Role of Ceramide 1-Phosphate in the Regulation of Cell Survival and Inflammation, *Biochemistry*, Prof. Deniz Ekinci (Ed.), ISBN: 978-953-51-0076-8, InTech, Available from: <http://www.intechopen.com/books/biochemistry/role-of-ceramide-1-phosphate-in-the-regulation-of-cell-survival-and-inflammation>

**INTECH**  
open science | open minds

#### **InTech Europe**

University Campus STeP Ri  
Slavka Krautzeka 83/A  
51000 Rijeka, Croatia  
Phone: +385 (51) 770 447  
Fax: +385 (51) 686 166  
[www.intechopen.com](http://www.intechopen.com)

#### **InTech China**

Unit 405, Office Block, Hotel Equatorial Shanghai  
No.65, Yan An Road (West), Shanghai, 200040, China  
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元  
Phone: +86-21-62489820  
Fax: +86-21-62489821

© 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

IntechOpen

IntechOpen